BioSpace News Archive

Should you be looking for another job? Or are you actually in a good employment situation, and simply being carried away by others’ experiences on LinkedIn or Facebook?

MorphoSys AG today presented data from the ongoing single-arm phase 2 clinical trial known as L-MIND in an oral presentation at the 60th American Society of Hematology (ASH) Annual Meeting 2018 in San Diego, USA.

A*STAR’s Institute of Microelectronics (IME) and One BioMed, an A*STAR spin-off, launched a S$9 million joint lab on Thursday (29 November).

Novartis is taking a treatment for persistent hives into Phase III trials after a mid-stage trial showed that the medication, ligelizumab (QGE031), outperformed Xolair in patients with chronic spontaneous urticaria (CSU) patients whose symptoms are inadequately controlled by H1-antihistamines.

At the American Society of Hematology meeting, companies are racing to develop a treatment for SCD, which is an inherited disorder caused by a genetic mutation in the beta-chain of hemoglobin. Some of the data presented by companies were promising, while others reported setbacks.

Nuformix, the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs, announces results from the completion of its innovative pre-clinical trial for its NXP002 fibrosis programme in human idiopathic pulmonary fibrosis (‘IPF’) against standard of care

Numerous studies have shown that a married individual is more likely to fare better battling cancer than a single individual, however, new anecdotal evidence may suggest that marital status can also impact the way an oncologist treats patients.

It should come as no surprise that not all information on the internet is reliable. It’s a largely unregulated wild, wild west that allows for anyone to put up any content they wish to. Which can be a particular problem when it comes to health-related content.

At the 60th American Society of Hematology (ASH) Annual Meeting & Exposition, Amgen released the first clinical data from two separate Phase I clinical trials of novel BiTE immunotherapies.

Seattle Genetics and Takeda show off the impressive survival data that prompted the FDA to give approval to Adcetris for this indication.